CTXR - Citius Pharmaceuticals, Inc.

0.8599
0.015   1.744%

Share volume: 163,434
Last Updated: 04-22-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.18%

PREVIOUS CLOSE
CHG
CHG%
$0.84
0.02
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 4%
Liquidity 43%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.64%
1 Month
14.47%
3 Months
1.16%
6 Months
-50.01%
1 Year
2.13%
2 Year
12.07%
Key data
Stock price
$0.86
P/E Ratio 
0.00
DAY RANGE
$0.84 - $0.89
EPS 
-$3.17
52 WEEK RANGE
$0.63 - $2.48
52 WEEK CHANGE
-$1.60
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
1.67
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$288,358
AVERAGE 30 VOLUME 
$385,364
Company detail
CEO: Leonard L. Mazur
Region: US
Website: citiuspharma.com
Employees: 20
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Citius Pharmaceuticals, Inc. engages in the development and commercialization of critical care products. The company is developing five proprietary products, including Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. MinoWrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, and Halo-Lido, a corticosteroid-lidocaine topical formulation.

Recent news